GlassScriptPhysician profile
Linh Truong
NPI 1346966132
$2,083.72
in general payments reported to CMS, 2019-2025
29 companies · $407 in 2025
The $407 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $579 · 2024: $1,098 · 2025: $407.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,014 · Education: $69.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,013.73 |
| Education | $69.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $306.85 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $268.90 | 2023-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $161.58 | 2023-2025 | Jardiance |
| Astellas Pharma US INC | $148.71 | 2025 | Veozah |
| Radius Health, INC. | $147.99 | 2023-2024 | Tymlos |
| Mannkind Corporation | $137.12 | 2023-2024 | Afrezza |
| Bayer Healthcare Pharmaceuticals INC. | $111.98 | 2023-2025 | |
| Xeris Pharmaceuticals, INC. | $79.60 | 2023-2024 | Gvoke Hypopen |
| Pfizer INC. | $77.55 | 2025 | |
| Ascendis Pharma Endocrinology INC | $69.47 | 2024 | |
| Cequr Corporation | $64.91 | 2023-2024 | Cequr Simplicity |
| Amgen INC. | $54.19 | 2024 | Evenity, Prolia, Otezla |
| Sanofi-Aventis U.S. LLC | $50.22 | 2023-2024 | |
| Organon LLC | $47.32 | 2025 | Nexplanon |
| Antares Pharma, INC. | $40.98 | 2024 | Xyosted |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $38.28 | 2024-2025 | Dexcom G6 Transmitter |
| Amneal Pharmaceuticals LLC | $33.05 | 2023-2024 | Unithroid |
| Acella Pharmaceuticals, LLC | $31.86 | 2023 | NP Thyroid 60 |
| Axsome Therapeutics, INC. | $25.30 | 2025 | Auvelity |
| Si-Bone, INC. | $23.90 | 2024 | |
| Ibsa Pharma INC. | $19.40 | 2024 | Tirosint, Licart |
| Corcept Therapeutics | $18.67 | 2024 | Korlym |
| Kyowa Kirin, INC. | $18.64 | 2024 | Crysvita |
| Amphastar Pharmaceuticals, INC. | $18.52 | 2024 | |
| Exact Sciences Corporation | $18.41 | 2023 | Cologuard Collection Kit |
| Ascensia Diabetes Care US INC. | $18.24 | 2025 | |
| Linus Health, INC. | $18.20 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $17.90 | 2023 | Farxiga |
| Esperion Therapeutics, INC. | $15.98 | 2024 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Linh Truong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.